Enzymatica partners to expand ColdZyme®in five European markets

Enzymatica AB (publ) today announces a partnership agreement with TheOTCLab for the marketing, sale and distribution of ColdZyme® in the UK, Ireland, the Netherlands, Belgium and Luxembourg.

The five markets have a combined population of more than 105 million and represent a significant opportunity to expand the ColdZyme® brand in Europe.

ColdZyme® is already established in the UK, where the brand has continued to grow strongly during 2026. The product is sold through Amazon UK and is listed at Boots, the UK's leading pharmacy, health and beauty retailer. The partnership transitions Enzymatica's UK business to a distributor model, with TheOTCLab building on the brand's existing position across e-commerce, pharmacy and wider retail, while launching ColdZyme® in Ireland, the Netherlands, Belgium and Luxembourg. The Benelux launches are planned for 2027.

The agreement follows Enzymatica's partnerships with STADA in Germany and Austria. It supports Enzymatica's strategy to expand internationally through established partners with strong local market access and the capabilities to develop ColdZyme® over time.

"TheOTCLab has presented a clear and ambitious plan for ColdZyme®. The partnership allows us to accelerate the existing UK business while expanding the brand into four new markets through one experienced consumer healthcare partner," says Sana Alajmovic, CEO of Enzymatica.

"ColdZyme® is a differentiated, clinically documented brand that fits well with our portfolio. We see strong potential to develop it across drugstore, pharmacy, e-commerce and the wider consumer healthcare market in all five countries," says Albert Swane, Founder & CEO of TheOTCLab.

For more information, please contact:
Sana Alajmovic, CEO, Enzymatica AB
E-mail: sana.alajmovic@enzymatica.com

About Enzymatica AB
Enzymatica AB (publ) is a Swedish life science company that develops and commercialises products for the treatment and relief of infections and symptoms affecting the upper respiratory tract. The company's proprietary barrier technology is based on a marine enzyme and forms the basis of its lead product, ColdZyme®. Enzymatica is headquartered in Lund, Sweden, and its shares are listed on Nasdaq First North Growth Market. The company's Certified Adviser is DNB Carnegie Investment Bank AB (publ).

About TheOTCLab

TheOTCLab is an Amsterdam-based consumer healthcare company that builds and scales OTC brands internationally. Founded in 2016, the company operates in more than 55 markets and has established commercial organisations in the UK, Germany, the Netherlands, Belgium, Luxembourg and Italy. The Financial Times ranked TheOTCLab among Europe's 1,000 fastest-growing companies in 2025 and 2026. Its portfolio includes Dr Yglo, FungeX, Acetocaustin, Breathe Right, Vagisil and Just For Men. TheOTCLab is B Corp certified and holds CE-MDR, ISO 13485 and MDSAP certification for medical devices.

Image Attachments

Enzymatica Sana Alajmovic
TheOTCLab Albert Swane
Coldzyme